T cell engagers in autoimmune diseases.

Area of Science:

• Immunology
• Biotechnology
• Pharmacology

Background:

• T cell engagers (TCEs) are engineered bispecific or multi-specific antibodies designed to redirect T cells towards target cells expressing specific surface antigens.
• Initially developed for oncology, TCEs are now showing promise in treating autoimmune diseases due to their potency and biologic advantages.

Purpose of the Study:

• To review the history, mechanism of action, and design principles of TCEs for autoimmune disease treatment.
• To discuss current challenges and future directions in the development of TCEs for autoimmunity.
• To provide an overview of the preclinical and clinical landscape of TCEs in autoimmune disease therapy.

Main Methods:

• Literature review of historical development, mechanism of action, and design principles of TCEs.
• Analysis of preclinical and clinical data for TCEs in autoimmune disease contexts.
• Discussion of challenges including safety, convenience, and target cell elimination.

Main Results:

• TCEs demonstrate comparable potency to cellular therapies with improved manufacturing, availability, safety, and delivery.
• Significant interest and promising initial results exist for TCEs in autoimmune disease treatment.
• Key challenges include enhancing safety, improving convenience, and ensuring complete target cell elimination.

Conclusions:

• TCEs represent a promising therapeutic modality for autoimmune diseases, leveraging biologic advantages.
• Further development is needed to address safety, convenience, and efficacy challenges for widespread clinical application.
• Next-generation TCEs are being optimized to broaden their application across various autoimmune conditions.